Industry
Biotechnology
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 5:53 pm
Portfolio Pulse from Benzinga Newsdesk
February 14, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
February 14, 2024 | 9:48 am
Portfolio Pulse from Avi Kapoor
January 05, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Newsdesk
January 05, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Newsdesk
January 04, 2024 | 9:34 pm
Portfolio Pulse from Benzinga Newsdesk
November 08, 2023 | 12:10 pm
Portfolio Pulse from Benzinga Insights
November 07, 2023 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2023 | 2:46 pm
Portfolio Pulse from Benzinga Newsdesk
October 12, 2023 | 10:34 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.